ijms-logo

Journal Browser

Journal Browser

Targeting Monoamine Oxidases: From Enzymatic Function to Pharmaceutical Use

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 6491

Special Issue Editor

Special Issue Information

Dear Colleagues,

Monoamine oxidases A and B (MAOA and MAOB) play an essential role in the oxidation of monoamines, and participate in the oxidative metabolism of both the central nervous system (CNS) and peripheral tissue. They are attached to the external membrane of mitochondria and oxidize the substrate amino group through the enzyme-bound FAD cofactor, which is then reoxidized by molecular oxygen with the release of hydrogen peroxide. MAOA and MAOB are involved in the regulation of concentrations of biogenic amines dopamine, noradrenaline, adrenaline, and serotonin in monoaminergic neurons and likely in other cell types. Their metabolism is still complex, as the distribution of MAOA and MAOB does not necessarily match the preferred biogenic amine substrate, and MAOA and MAOB are also involved in the degradation of some their metabolites.

MAOA and/or MAOB are a possible target in a number of diseases related to oxidative stress and biogenic amine defects. MAOB inhibitors are given in the treatment of Parkinson’s disease, whereas mixed MAOA/B or MAOA inhibitors have antidepressant properties. Their antioxidant properties repurpose their use in neurodegenerative diseases, notably Alzheimer’s disease, stroke, cardiovascular diseases, and obesity, to cite a few. Naturally ingested compounds, such as harmane, curcumin, and b-carbolines are potential antioxidant compounds that have an inhibitory effect on MAOs. Some of them, not always fully identified, are thought to participate in the psychoactive action of tobacco or ayahuasca by reducing MAO activity. These natural compounds serve to develop several series of potent MAO inhibitors, while the availability of MAO crystal structures has led to the optimization of drug design in in silico studies. Chemical research in the field of MAO is very active to produce either new potent and selective compounds or multitarget drugs that show inhibitory activity on MAOs.

The path is quite clear, but there are still many questions on their function that start from the reaction of the catalyse itself, which can be apprehended either experimentally or through computational studies. Their impact on the metabolism of amines and biogenic amines is still opaque. The MAO blockade has consequences on endogenous monoamines, trace amine concentrations, and exogenous amines from alimentation. The regulation of their expression, the modification of their activity through drugs or environmental conditions, and the existence of polymorphisms could produce monoamine imbalance. Thus, a further step in understanding the implication of MAOs in diseases regards the availability of PET radioligand tools aiming at revealing the distribution and quantity of MAOA/B in various conditions in preclinical and clinical studies.

The purpose of this Special Issue is to collect research articles and reviews at different levels of analysis dealing with the functions of MAOA and MAOB, and the development of inhibitors. Chemical, molecular, biochemical, and biological studies are welcome in this Special Issue.

Prof. Philippe De Deurwaerdère
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Monoamine oxidase inhibitor
  • biochemistry
  • amine metabolism
  • behaviour
  • peripheral organs
  • central nervous system
  • neurochemistry
  • oxidative stress
  • neurodegenerative disease

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1755 KiB  
Article
Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study
by Tana Tandarić, Alja Prah, Jernej Stare, Janez Mavri and Robert Vianello
Int. J. Mol. Sci. 2020, 21(17), 6151; https://doi.org/10.3390/ijms21176151 - 26 Aug 2020
Cited by 12 | Viewed by 3274
Abstract
Monoamine oxidases (MAOs) catalyze the degradation of a very broad range of biogenic and dietary amines including many neurotransmitters in the brain, whose imbalance is extensively linked with the biochemical pathology of various neurological disorders, and are, accordingly, used as primary pharmacological targets [...] Read more.
Monoamine oxidases (MAOs) catalyze the degradation of a very broad range of biogenic and dietary amines including many neurotransmitters in the brain, whose imbalance is extensively linked with the biochemical pathology of various neurological disorders, and are, accordingly, used as primary pharmacological targets to treat these debilitating cognitive diseases. Still, despite this practical significance, the precise molecular mechanism underlying the irreversible MAO inhibition with clinically used propargylamine inhibitors rasagiline and selegiline is still not unambiguously determined, which hinders the rational design of improved inhibitors devoid of side effects current drugs are experiencing. To address this challenge, we present empirical valence bond QM/MM simulations of the rate-limiting step of the MAO inhibition involving the hydride anion transfer from the inhibitor α-carbon onto the N5 atom of the flavin adenin dinucleotide (FAD) cofactor. The proposed mechanism is strongly supported by the obtained free energy profiles, which confirm a higher reactivity of selegiline over rasagiline, while the calculated difference in the activation Gibbs energies of ΔΔG = 3.1 kcal mol−1 is found to be in very good agreement with that from the measured literature kinact values that predict a 1.7 kcal mol−1 higher selegiline reactivity. Given the similarity with the hydride transfer mechanism during the MAO catalytic activity, these results verify that both rasagiline and selegiline are mechanism-based irreversible inhibitors and offer guidelines in designing new and improved inhibitors, which are all clinically employed in treating a variety of neuropsychiatric and neurodegenerative conditions. Full article
Show Figures

Graphical abstract

20 pages, 3591 KiB  
Article
Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors
by Dorota Łażewska, Agnieszka Olejarz-Maciej, David Reiner, Maria Kaleta, Gniewomir Latacz, Małgorzata Zygmunt, Agata Doroz-Płonka, Tadeusz Karcz, Annika Frank, Holger Stark and Katarzyna Kieć-Kononowicz
Int. J. Mol. Sci. 2020, 21(10), 3411; https://doi.org/10.3390/ijms21103411 - 12 May 2020
Cited by 11 | Viewed by 2590
Abstract
Dual target ligands are a promising concept for the treatment of Parkinson’s disease (PD). A combination of monoamine oxidase B (MAO B) inhibition with histamine H3 receptor (H3R) antagonism could have positive effects on dopamine regulation. Thus, a series of [...] Read more.
Dual target ligands are a promising concept for the treatment of Parkinson’s disease (PD). A combination of monoamine oxidase B (MAO B) inhibition with histamine H3 receptor (H3R) antagonism could have positive effects on dopamine regulation. Thus, a series of twenty-seven 4-tert-butylphenoxyalkoxyamines were designed as potential dual-target ligands for PD based on the structure of 1-(3-(4-tert-butylphenoxy)propyl)piperidine (DL76). Probed modifications included the introduction of different cyclic amines and elongation of the alkyl chain. Synthesized compounds were investigated for human H3R (hH3R) affinity and human MAO B (hMAO B) inhibitory activity. Most compounds showed good hH3R affinities with Ki values below 400 nM, and some of them showed potent inhibitory activity for hMAO B with IC50 values below 50 nM. However, the most balanced activity against both biological targets showed DL76 (hH3R: Ki = 38 nM and hMAO B: IC50 = 48 nM). Thus, DL76 was chosen for further studies, revealing the nontoxic nature of DL76 in HEK293 and neuroblastoma SH-SY5Ycells. However, no neuroprotective effect was observed for DL76 in hydrogen peroxide-treated neuroblastoma SH-SY5Y cells. Furthermore, in vivo studies showed antiparkinsonian activity of DL76 in haloperidol-induced catalepsy (Cross Leg Position Test) at a dose of 50 mg/kg body weight. Full article
Show Figures

Figure 1

Back to TopTop